118 related articles for article (PubMed ID: 6201419)
1. The current status of drug development of hypoxic cell radiosensitizers and their potential role in gynecologic oncology.
Coleman CN; Ballon SC; Howes AE; Martinez A; Halsey J; Hirst VK
Gynecol Oncol; 1984 May; 18(1):18-27. PubMed ID: 6201419
[TBL] [Abstract][Full Text] [Related]
2. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials of radiosensitizers: what should we expect?
Brown JM
Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272
[TBL] [Abstract][Full Text] [Related]
4. In vitro assessment of the oncogenic potential of nitroimidazole radiosensitizers.
Hei TK; Geard CR; Osmak RS; Hall EJ
Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1653-8. PubMed ID: 3839777
[TBL] [Abstract][Full Text] [Related]
5. The neurotoxicity of radiosensitizing drugs: a biochemical assessment of desmethylmisonidazole (DMM) in the rat.
Rose GP; Taylor JM
Toxicology; 1985 Jan; 34(1):43-56. PubMed ID: 3918357
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic transforming potential of nitroimidazole radiosensitizers.
Hall EJ; Hei TK
Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1231-4. PubMed ID: 2523882
[TBL] [Abstract][Full Text] [Related]
7. Misonidazole with dexamethasone rescue: an escalating dose toxicity study.
Tanasichuk H; Urtasun RC; Fulton DS; Raleigh J
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1735-7. PubMed ID: 6480455
[TBL] [Abstract][Full Text] [Related]
8. Neuropathy of nitroimidazole radiosensitizers: clinical and pathological description.
Wasserman TH; Nelson JS; VonGerichten D
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1725-30. PubMed ID: 6237085
[TBL] [Abstract][Full Text] [Related]
9. Behavioural and ultrastructural studies of desmethylmisonidazole-induced neurotoxicity in mice.
Chao CF; Subjeck JR; Johnson RJ
Br J Radiol; 1983 Jan; 56(661):27-31. PubMed ID: 6821740
[TBL] [Abstract][Full Text] [Related]
10. Hypoxic cell radiosensitizers: expectations and progress in drug development.
Coleman CN
Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):323-9. PubMed ID: 3156109
[TBL] [Abstract][Full Text] [Related]
11. The potential for radiation sensitizers and radiation protectors combined with radiation therapy in gynecologic cancer.
Brady LW; Phillips TL; Wasserman TH
Cancer; 1981 Jul; 48(2 Suppl):650-7. PubMed ID: 6268288
[TBL] [Abstract][Full Text] [Related]
12. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
[TBL] [Abstract][Full Text] [Related]
13. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Noll L; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1990 Feb; 18(2):389-93. PubMed ID: 2154420
[TBL] [Abstract][Full Text] [Related]
14. Hypoxic cell radiosensitizers--present and future.
Wasserman TH
Int J Radiat Oncol Biol Phys; 1981 Jun; 7(6):849-52. PubMed ID: 6457019
[No Abstract] [Full Text] [Related]
15. Neurotoxicity with desmethylmisonidazole.
Dische S; Saunders MI; Stratford MR
Br J Radiol; 1981 Feb; 54(638):156-7. PubMed ID: 6257319
[No Abstract] [Full Text] [Related]
16. A comparison of the cytological effects of three hypoxic cell radiosensitizers.
Spunberg JJ; Geard CR; Rutledge-Freeman MH
Int J Radiat Oncol Biol Phys; 1982 Jul; 8(7):1207-15. PubMed ID: 6214532
[TBL] [Abstract][Full Text] [Related]
17. Newly synthesized hypoxia-mediated drugs as radiosensitizers and cytotoxic agents.
Astor M; Hall EJ; Biaglow JE; Parham JC
Int J Radiat Oncol Biol Phys; 1982 Jan; 8(1):75-83. PubMed ID: 7061257
[TBL] [Abstract][Full Text] [Related]
18. Initial pharmacology and toxicology of intravenous desmethylmisonidazole.
Coleman CN; Wasserman TH; Phillips TL; Strong JM; Urtasun RC; Schwade JG; Johnson RJ; Zagars G
Int J Radiat Oncol Biol Phys; 1982; 8(3-4):371-5. PubMed ID: 7107354
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
Coleman CN; Wasserman TH; Urtasun RC; Halsey J; Hirst VK; Hancock S; Phillips TL
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1105-8. PubMed ID: 3017904
[TBL] [Abstract][Full Text] [Related]
20. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
Dische S; Saunders MI; Flockhart IR
Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
